

Houlihan Lokey


-4 →

Urological Care Industry Sector Spotlight

Winter 2024

Urology Market Overview

The \$77 billion urologic services industry is a large medical specialty with a compelling growth trajectory.



... Providing Compelling Characteristics for Investment

Highly Attractive Market...

Significant scale is required to leverage all available urological ancillaries, providing an opportunity for leading, integrated platforms to outpace other PPM subspecialties in addressable revenue per physician, organic growth, and physician compensation potential

Urology Care "101"

3

Houlihan Lokey

Urology care covers a wide range of medical conditions, treatments, and care types. The overwhelming majority of spend is tied to urgent conditions that necessitate timely treatment.

	Conditions	Total U.S. Spend (2022) ⁽¹⁾		
\otimes	Urologic Cancer	\$20B		
(ZFE)	Urologic Stones	\$14B		
	Urologic Infections	\$7B		
$\bigcirc^{\!$	Benign Prostatic Hyperplasia	\$6B		
Q	Female Bladder Conditions	\$5B		
R	Uro-Gynecologic Conditions	\$5B		
Q	Erectile Dysfunction/Infertility	\$4B		
•••	Other ⁽²⁾	\$9B		
	Sources: Market research National Consultina Firm	\$70B Total U.S. Spend		

Recession-resilient specialty—90%+ of spend attributable to procedures and treatments that cannot be materially delayed or avoided


Sources: Market research, National Consulting Firm.

(1) By condition spend is the most recent data available (2022).

(2) Includes complications related to kidney transplants and other miscellaneous conditions.

Why Investors Should Be Excited About Urology

Demographic tailwinds and fragmented market dynamics provide a one-of-a-kind opportunity to investors within specialty PPM.



Urology Highlights

Urologists quarterback the patient journey, driving higher Ancillaries require scale and capital to access, which result in better addressable spend per physician than other PPM specialties quality of care across the patient continuum Aging population and non-deferrable nature of treatment provides Of the five PE-backed urology platforms in the U.S., only three have stability, recession resiliency, and near-term growth tailwinds the scale required to offer full ancillary coverage Sources: Market research, National Consulting Firm. 4

Houlihan Lokey

Why Urology Over Other Specialties?

Professional	Outpatient Inpatient					
Specialty	Total Addressable Spend (\$B)	CAGR (2017–2022)	Number of Physicians ⁽¹⁾	Addressable Spend per Physician ⁽¹⁾	Ancillary Services Opportunity	Major Ancillary Services
Urology	\$23 \$28 \$13 \$64	~7%	~14K	~\$3.6M		 ASCs Pathology Intensity-Modulated Radiation Therapy Infusion/Dispensing
Gastroenterology	\$29 \$23 \$12 \$64	~3%	~16K	~\$3.2M		ASCsInfusionsPathology
Women's Health	\$31 \$22 \$30 \$83	~4%	~42K	~\$1.3M		ImagingLab Services
Ear, Nose, and Throat	\$11 \$12 \$8 \$31	~4%	~10K	~\$2.4M		ASCsAllergy TestingInfusions
Dermatology	\$3 \$17 \$20	~8%	~13K	~\$1.5M		Mohs SurgeriesPathology
Ophthalmology	\$1 \$30 \$8 \$39	~5%	~18K	~\$2.4M		Ancillary Testing

Urology is ideally positioned versus other PPM subspecialties given market size and growth, attractive site-of-care dynamics, and significant ancillary opportunities that drive high addressable spend per physician

Houlihan Lokey
Source: National Consulting Firm.
(1) Most recent data available (20)

5

(1) Most recent data available (2021); inpatient facility fees excluded due to limited data availability.

What Investors Value

Houlihan Lokey's unmatched experience has provided a proprietary view of varying factors that help drive buyers to a premium valuation for urology platforms.

		Value Consideration	Impact on Value	Commentary
	Organic Same-Practice Growth	What does the sustainable go- forward same-practice growth profile look like?	High Critical	 Demonstrated sustainable organic growth from ancillary insourcing and/or ancillary build-out Focus on recruiting providers and leveraging APPs to position physicians in ASC to capture site-of-care shift
	Track Record of Income Repair	What has it looked like historically, and what are the components that drive higher income repair?	High Critical	 Track record of generating income repair for existing physicians, with contribution from ancillary initiatives Demonstrated income repair for recently acquired physicians in new markets, further validating income repair playbook
	Ancillary Capabilities	How comprehensive is the ancillary suite, and what is the roadmap to add new ancillaries moving forward?	High Critical	 Track record of building out ancillaries, including ASCs, infusions, pharmacy dispensing, and pathology Ability to articulate the economic impact and go-forward playbook in new and existing markets
ΣŢŢ	Physician Alignment	How are physicians aligned and incentivized, through compensation and clinical autonomy, throughout the platform?	High Critical	 Strong buy-in among doctor leaders, including consistent physician rollover in M&A and strong go-forward appetite Alignment through shared ASC ownership, productivity-based compensation, and meaningful ancillary distributions
۲	Sophisticated MSO Infrastructure	How does MSO infrastructure drive operational efficiency, scalability, and patient experience?	High Critical	 Robust infrastructure that exemplifies operational excellence, integrating all practices for efficient and compliant care delivery Single EMR and ERP across MSO allows for coordination between practices and seamless, frequent reporting
1755	Proven M&A Sophistication & Integration	What is the M&A strategy and level of replicability across markets?	High Critical	 Disciplined approach, established integration playbook, M&A infrastructure, and tech systems. Proven post-acquisition performance establishes confidence in the playbook

Significant Scale Required to Benefit From Ancillary Opportunities in Urology

Large and growing urology platforms with sufficient scale and resources are uniquely positioned to integrate complementary ancillary services—accelerating growth, diversifying revenue streams, and facilitating long-term growth.

		Description	Start-Up Requirement	Minimum Doctor Count		
	ASCs	Low-cost, ambulatory facility to perform procedures	~\$2M-\$3M	5+ Urologists		
ي ا	Pharmacy	On-site pharmacies to dispense medications	Pharmacist and staff; inventory management system	15+ Urologists		
	Intensity-Modulated Radiation Therapy	Intensity-modulated radiation therapy for cancer patients	~\$5M (equipment and specialized facility infrastructure)	10+ Urologists		
0	Interventional Radiology	Imaging to diagnose and treat cancer without major surgery	~\$1M-\$2M	10+ Urologists		
	Pathology	In-house pathology lab to process samples	Pathologist, pathology manager, support staff	15+ urologists		
	Clinical Research	Clinical research team to manage clinical trials	Dedicated research director and coordinator	10+ Urologists		
	Infusions and Injectables	Infusions and injections used for treatment	No investment required	1+ Urologist		
Integration of ancillary services requires a scaled urology platform to be economically viable						
	ility to Diversify evenue Streams	Opportunity to Integrate Full-Scope Urology Services	Potential to Capitalize on Margin Expansion	Provide More Comprehensive Patient Care		


Houlihan Lokey

Sources: Market research, National Consulting Firm.

7

Integrated Urology Practices 'Own' the Patient Journey

Integrated, scaled urology platforms drive a seamless patient experience and positive clinical outcomes by "owning" the care journey. Value is added to payors, referral sources, patients, and providers.




Urology Platforms Well Positioned to Benefit From Site-of-Care Shift

Urology care today occurs mostly in hospitals, but there is significant potential for volume to continue to shift to outpatient settings owned by independent, scaled practices.

Transition to Outpatient Settings Is Supported by Attractive Payor Rates

- Urology is still early in the site-of-care shift—in 2021, 11% of addressable procedures were performed in an ASC⁽¹⁾
- ASC setting provides the strongest value proposition to all stakeholders:
 - Physicians: Increased efficiency and ability to participate in facility fee economics
 - **Patients**: Faster access to care and higher satisfaction compared to hospitals
 - Payors: Lower costs, superior care quality, and improved member experience and outcomes
- Smaller practices lack the scale to access ASCs; significant room for future growth and opportunities for scaled platforms to benefit

(1) Most recent data available.





Reimbursement Dynamics in Urology

Payors are not expected to materially alter reimbursement rates in urology and continue to be supportive of the ongoing shift in the site of service to ASCs.

Key Drivers of Positive Reimbursement Outlook

Increased Utilization

- Payors view shifting services to lower cost settings as the most important utilization management technique
- Payors are prioritizing site-of-care shift and are not expected to actively manage utilization within urology

Urology Reimbursement Outlook

10

Cumulative Increase in Reimbursement Rates Relative to Today



Site-of-Care Shift


- There has been a steady shift in the site of service to ASCs; scaled, integrated urology players are best positioned to build and operate outpatient ASC facilities
- The increase in percentage of services performed in ASCs is overwhelmingly supported by payors due to their cost effectiveness and equal or better clinical outcomes

Medicare Advantage



Stable Reimbursement

- Urology reimbursement is expected to remain stable with modest rate uplift opportunity, consistent with other surgical specialties that are lower on the health plan priority list in terms of utilization and spend
- Payors do not perceive urology as an area of focus relative to other specialties and had generally positive sentiments about the sector



Commercial

Houlihan Lokey Sources: Market research, National Consulting Firm.


Market and Competitive Landscape



Only three platforms with multi-state scale/coverage, coupled with a low overall percentage of PE-affiliated urologists, leaves significant whitespace for expansion

Featured Urology Platforms to Watch

Multiple PE-backed platforms are nearing the end of potential hold periods, providing attractive points of entry into the category.



About Our Firm



Houlihan Lokev

Houlihan Lokey is a leading global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, and financial and valuation advisory.

Our firm is the trusted advisor to more top decision-makers than any other independent global investment bank.

We invite you to learn more about how our bankers can serve your needs:

LEARN MORE ABOUT 🔀

Corporate Finance

Financial Restructuring

Financial and Valuation Advisory

Our Industry Coverage

Houlihan Lokey 13

Key Facts and Figures



Our Ranking by Service

Corporate Finance

2023 M&A Advisory Rankings

Houlihan Lokey

Goldman Sachs & Co

Rothschild & Co

Morgan Stanley

No. 1 Global M&A Advisor

Leading Capital Markets Advisor

All Global Transactions

JP Morgan

Source: LSEG (formerly Refinitiv).

1

2

3

3

5

36 Locations worldwide

Deals

352

349

300

300

253

~2,000 312 Total financial professionals

Managing Directors⁽¹⁾ 2,000+ Clients served annually

\$8.3B Market

1999-2023 Global M&A

JP Morgan

UBS

1

2

3

4

5

Fairness Advisory Rankings

Houlihan Lokey

Morgan Stanley

Announced or completed transactions

Source: LSEG (formerly Refinitiv).

Over the Past 25 Years

Capitalization⁽²⁾

Financial and Valuation Advisory

Duff & Phelps, A Kroll Business

No. 1 Global M&A Fairness Opinion Advisor

1,000+ Annual Valuation Engagements

\$1.8B Revenue⁽³⁾

Deals

1,247

1,035

977

884

716

Financial Restructuring

	3 Global Distressed Debt & Ikruptcy Restructuring Rankings	
	Advisor	Deals
1	Houlihan Lokey	73
2	PJT Partners Inc	64
3	Rothschild & Co	51
4	Lazard	37
5	Evercore Partners	27
Sour	ce: LSEG (formerly Refinitiv).	

No. 1 Global Restructuring Advisor

1,700+ Transactions Completed Valued at More Than \$3.5 Trillion Collectively

Fully Integrated Financial Sponsor Coverage



AMERICAS

Dallas

Miami Minneapolis

Houston

Los Angeles

Atlanta

Boston

Baltimore

Charlotte

Chicago

Houlihan Lokey Is a Global Firm

New York

São Paulo

San Francisco

Washington, D.C.

Sponsors covered, providing market insights and knowledge of buyer behavior

Stockholm

Tel Aviv

Zurich

Companies sold to financial sponsors over the past five vears

EUROPE AND MIDDLE EAST

ASIA-PACIFIC Beijing Shanghai Singapore

Fukuoka Gurugram Hong Kong SAR Mumbai

Sydney Tokyo

(1) As of December 31, 2023, excludes corporate MDs. (2) As of January 31, 2024. (3) LTM ended December 31, 2023.

Amsterdam

Antwerp.

Frankfurt

London

Dubai

Madrid

Milan

Paris

Munich

Manchester

About Our Healthcare Industry Group



Houlihan Lokev

Houlihan Lokey's Healthcare Group has earned a reputation for providing superior service and achieving outstanding results in M&A advisory, capital raising, restructuring, and financial and valuation advisory services.

We provide in-depth knowledge, proven transaction experience, and an exceptional level of service to our clients.

2023 M&A Advisory Rankings All Global Healthcare Transactions				
	Advisor	Deals		
1	Houlihan Lokey	34		
2	Jefferies LLC	31		
2	Rothschild & Co	31		
4	Centerview Partners LLC	30		
4	Goldman Sachs & Co	30		
Source: LSEG (formerly Refinitiv). Excludes accounting firms and brokers.				

LEARN MORE ABOUT \mathbb{R} **Our Healthcare**

Industry Coverage

Key Facts and Figures

No. 1 M&A Advisor for All Global Healthcare Transactions

90 +**Dedicated Healthcare Financial Professionals**

200 +**Transactions Closed Since** 2016, the Most by Any Firm

Industry Sector Coverage

We cover a broad array of sectors, with bankers dedicated to each of our primary coverage areas



















Behavioral Distribution

Global Healthcare Technology

Global Pharmaceuticals

Pharmaceutical

Services

Health Systems and Hospitals

Hospital/Outpatient Clinical and Outsourced Services



Outpatient Services



Oral Health



Services

Payor and Employer





Physician Practice Management

Post-Acute/Senior Housing

Retail Healthcare

Global Medical Technology Products and

Services

Selected Healthcare Industry Transactions

Pharmacv



Tombstones included herein represent transactions closed from 2020 forward.

Houlihan Lokey 14

About Our Urology Team

Unparalleled Expertise Across the Broader Multisite/PPM Landscape

Urology Team



Mike Pisani Managing Director Co-Head of U.S. Healthcare <u>MPisani@HL.com</u> +1 214.665.8611



Brandon Breslow Senior Vice President Brandon.Breslow@HL.com +1 609.206.3283



Patrick Pontani Associate Patrick.Pontani@HL.com +1 917.969.1265

Other Supporting Team Members



Mark Francis Managing Director Global Head of Healthcare MFrancis@HL.com +1 214.220.8484




Colby Catania Senior Vice President CCatania@HL.com +1 860 484 9389

CONTACT US



Please reach out to us to schedule a call to discuss insights on the sector or to explore how we can serve your business needs.



Disclaimer

© 2024 Houlihan Lokey. All rights reserved. This material may not be reproduced in any format by any means or redistributed without the prior written consent of Houlihan Lokey.

Houlihan Lokey is a trade name for Houlihan Lokey, Inc., and its subsidiaries and affiliates, which include the following licensed (or, in the case of Singapore, exempt) entities: in (i) the United States: Houlihan Lokey Capital, Inc., and Houlihan Lokey Advisors, LLC, each an SEC-registered broker-dealer and member of FINRA (www.finra.org) and SIPC (www.sipc.org) (investment banking services); (ii) Europe: Houlihan Lokey Advisory Limited, Houlihan Lokey EMEA, LLP, Houlihan Lokey (Corporate Finance) Limited, and Houlihan Lokey UK Limited, authorized and regulated by the U.K. Financial Conduct Authority; Houlihan Lokey (Europe) GmbH, authorized and regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht); (iii) the United Arab Emirates, Dubai International Financial Centre (Dubai): Houlihan Lokey (MEA Financial Advisory) Limited, regulated by the Dubai Financial Services Authority for the provision of advising on financial products, arranging deals in investments, and arranging credit and advising on credit to professional clients only; (iv) Singapore: Houlihan Lokey (Singapore) Private Limited and Houlihan Lokey Advisers Singapore Private Limited, each an "exempt corporate finance adviser" able to provide exempt corporate finance advisory services to accredited investors only; (v) Hong Kong SAR: Houlihan Lokey (China) Limited, licensed in Hong Kong by the Securities and Futures Commission to conduct Type 1, 4, and 6 regulated activities to professional investors only; (vi) India: Houlihan Lokey Advisory (India) Private Limited, registered as an investment adviser with the Securities and Exchange Board of India (registration number INA000001217); and (vii) Australia: Houlihan Lokey (Australia) Pty Limited (ABN 74 601 825 227), a company incorporated in Australia and licensed by the Australian Securities and Investments Commission (AFSL number 474953) in respect of financial services provided to wholesale clients only. In the United Kingdom, European Economic Area (EEA), Dubai, Singapore, Hong Kong, India, and Australia, this communication is directed to intended recipients, including actual or potential professional clients (UK, EEA, and Dubai), accredited investors (Singapore), professional investors (Hong Kong), and wholesale clients (Australia), respectively. No entity affiliated with Houlihan Lokey, Inc., provides banking or securities brokerage services and is not subject to FINMA supervision in Switzerland or similar regulatory authorities in other jurisdictions. Other persons, such as retail clients, are NOT the intended recipients of our communications or services and should not act upon this communication.

Houlihan Lokey gathers its data from sources it considers reliable; however, it does not guarantee the accuracy or completeness of the information provided within this presentation. The material presented reflects information known to the authors at the time this presentation was written, and this information is subject to change. Any forward-looking information and statements contained herein are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, past performance should not be taken as an indication or guarantee of future performance, and information contained herein may be subject to variation as a result of currency fluctuations. Houlihan Lokey makes no representations or warranties, expressed or implied, regarding the accuracy of this material. The views expressed in this material accurately reflect the personal views of the authors regarding the subject securities and issuers and do not necessarily coincide with those of Houlihan Lokey. Officers, directors, and partners in the Houlihan Lokey group of companies may have positions in the securities of the companies discussed. This presentation does not constitute advice or a recommendation, offer, or solicitation with respect to the securities of any company discussed herein, is not intended to provide information upon which to base an investment decision, and should not be construed as such. Houlihan Lokey or its affiliates may from time to time provide financial or related services to these companies. Like all Houlihan Lokey employees, the authors of this presentation receive compensation that is affected by overall firm profitability.



CORPORATE FINANCE FINANCIAL RESTRUCTURING FINANCIAL AND VALUATION ADVISORY

HL.com